Vivus Inc (VVUS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Vivus Inc (VVUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9935
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Vivus Inc (Vivus) is a biopharmaceutical company which develops and commercializes next-generation therapeutics for addressing unmet needs in obesity, sleep apnea, diabetes and sexual health. The company’s marketed products include, Qsymia (phentermine and topiramate extended-release), indicated for the chronic weight management in adult patients; and Stendra/Spedra (avanafil), an oral phosphodiesterase type 5, for erectile dysfunction. Its pipeline products include Qsymia for obstructive sleep apnea, nonalcoholic steatohepatitis, diabetes, nonalcoholic fatty liver disease and hyperlipidemia; and Tacrolimus for pulmonary arterial hypertension. Vivus works in partnership with pharmaceutical companies to advance of its product portfolio. It operates through its subsidiaries in the UK, the Netherlands, Ireland and Bermuda. Vivus is headquartered in Campbell, California, the US.

Vivus Inc (VVUS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Vivus Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 11
Vivus Acquires Topiramate Related Patents from Janssen Pharma 12
Venture Financing 13
Athyrium Opportunities Invests in Vivus 13
Partnerships 14
Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 14
Licensing Agreements 15
VIVUS Enters into Licensing Agreement with Selten Pharma 15
Hetero Enters into Licensing Agreement with VIVUS for STENDRA 16
Metuchen Pharma Enters into Licensing Agreement with Vivus 17
Vivus Enters Into Licensing Agreement With Menarini For Spedra 18
Equity Offering 20
Vivus Plans to Raise up to USD200 Million in Public Offering of Securities 20
VIVUS Completes Public Offering Of Common Stock For US$202 Million 21
Debt Offering 23
Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 23
Vivus Completes Private Placement of Notes Due 2020 For US$220 Million 24
Acquisition 25
Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 25
Vivus Inc – Key Competitors 26
Vivus Inc – Key Employees 27
Vivus Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2018: VIVUS reports third quarter 2018 financial results 29
Aug 07, 2018: VIVUS reports second quarter 2018 financial results 31
May 08, 2018: VIVUS Reports First Quarter 2018 Financial Results 33
Mar 13, 2018: VIVUS Reports Fourth Quarter 2017 Financial Results 35
Nov 07, 2017: VIVUS Reports Third Quarter 2017 Financial Results 37
Aug 03, 2017: VIVUS Reports Second Quarter 2017 Financial Results 39
May 03, 2017: VIVUS Reports 2017 First Quarter Financial Results 41
Mar 08, 2017: VIVUS Reports Fourth Quarter and Full Year 2016 Financial Results 42
Corporate Communications 44
Oct 29, 2018: VIVUS adds two new members to the Board of Directors 44
Sep 21, 2018: VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundation’s CF Climb 45
Aug 06, 2018: VIVUS names Kenneth Suh as president 47
Dec 26, 2017: VIVUS Announces Change in Leadership 48
May 24, 2017: Thomas B. King Joins VIVUS’ Board of Directors 49
Product Approvals 50
Nov 02, 2017: VIVUS Completes Tacrolimus Pre-IND Meeting With FDA 50
Clinical Trials 51
Jul 10, 2018: VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Vivus Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vivus Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Vivus Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
VIVUS Acquires Assets from Janssen Pharma for USD135 Million 11
Vivus Acquires Topiramate Related Patents from Janssen Pharma 12
Athyrium Opportunities Invests in Vivus 13
Vivus Plans To Enter Into Co-Marketing Agreement For Qsymia 14
VIVUS Enters into Licensing Agreement with Selten Pharma 15
Hetero Enters into Licensing Agreement with VIVUS for STENDRA 16
Metuchen Pharma Enters into Licensing Agreement with Vivus 17
Vivus Enters Into Licensing Agreement With Menarini For Spedra 18
Vivus Plans to Raise up to USD200 Million in Public Offering of Securities 20
VIVUS Completes Public Offering Of Common Stock For US$202 Million 21
Vivus to Raise Funds through public offering of 4.5% Convertible Bonds Due 2020 23
Vivus Completes Private Placement of Notes Due 2020 For US$220 Million 24
Aspen Investment Plans to Acquire Remaining Interest in Vivus for USD640 Million 25
Vivus Inc, Key Competitors 26
Vivus Inc, Key Employees 27
Vivus Inc, Subsidiaries 28

List of Figures
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Vivus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Vivus Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Vivus Inc (VVUS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Taiwan Semiconductor Manufacturing Company Limited:企業の戦略・SWOT・財務分析
    Taiwan Semiconductor Manufacturing Company Limited - Strategy, SWOT and Corporate Finance Report Summary Taiwan Semiconductor Manufacturing Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's struct …
  • Tailored Brands, Inc.:企業の戦略・SWOT・財務情報
    Tailored Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tailored Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • ASIT Biotech SA (ASIT):製薬・医療:M&Aディール及び事業提携情報
    Summary ASIT Biotech SA (ASIT Biotech), formerly BioTech Tools SA is a clinical stage biopharmaceutical company that develops in-vitro and in-vivo biotech tools. The company develops and commercializes immunotherapy medicines for respiratory and food allergies using ASIT plus technology platform. It …
  • Contact Energy Ltd:発電所・企業SWOT分析
    Contact Energy Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • TVEL Fuel Co:企業の戦略的SWOT分析
    TVEL Fuel Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Bank Of The Philippine Islands:企業の戦略・SWOT・財務分析
    Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report Summary Bank Of The Philippine Islands - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Newfield Exploration Company (NFX):石油・ガス:M&Aディール及び事業提携情報
    Summary Newfield Exploration Co (Newfield) is an independent upstream company. The company focuses on onshore large scale, liquids-rich resource plays. Its domestic assets are in the Anadarko and Arkoma basins of Oklahoma, the Williston Basin of North Dakota and the Uinta Basin of Utah. The company …
  • Jindal Hotels Ltd:企業の戦略・SWOT・財務情報
    Jindal Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Jindal Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Larix AS:製薬・医療:M&Aディール及び事業提携情報
    Summary Larix A/S (Larix) is a contract research organization that offers services related to clinical trials assistance. The organization provides services such as statistics, data management, clinical research, pharmacovigilance and data monitoring among others. It offers services across all phase …
  • Chugai Pharmaceutical Co Ltd (4519):製薬・医療:M&Aディール及び事業提携情報
    Summary Chugai Pharmaceutical Co Ltd (Chugai) is a subsidiary of Hoffmann-La Roche Ltd, which focuses on the research, development, manufacture, commercialization, import and export of the biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone an …
  • ClearOne Inc (CLRO):企業の財務・戦略的SWOT分析
    Summary ClearOne Inc (ClearOne) formerly ClearOne Communications Inc, is a technology company that provides conferencing, collaboration, streaming, and digital signage solutions. The company provides professional conferencing, audio and video distribution, premium conferencing, tabletop conferencing …
  • CITIC Pacific Limited:企業のM&A・事業提携・投資動向
    CITIC Pacific Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CITIC Pacific Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Delegat’s Group Limited:企業の戦略・SWOT・財務分析
    Delegat's Group Limited - Strategy, SWOT and Corporate Finance Report Summary Delegat's Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Antilles Oil and Gas NL (AVD):石油・ガス:M&Aディール及び事業提携情報
    Summary Antilles Oil and Gas NL (Antilles) is an upstream oil and gas company that carries out the acquisition and exploration of petroleum and gas properties. The company acquires underperforming assets and re-evaluates to identify untapped recoverable reserves. The company’s operates an exploratio …
  • Vectrus Inc (VEC):企業の財務・戦略的SWOT分析
    Vectrus Inc (VEC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • EnGeneIC Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary EnGeneIC Ltd (EnGeneIC) is a biopharmaceutical company that develops drugs and other therapeutic molecules. The company develops nanocell platform used as a platform for the creation of custom therapies for cancer. Its cyto-immunotherapy platform releases concentrations of RNA-interference m …
  • Inabata & Co Ltd (8098):企業の財務・戦略的SWOT分析
    Inabata & Co Ltd (8098) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • West Japan Railway Co (9021):企業の財務・戦略的SWOT分析
    West Japan Railway Co (9021) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Valmet Corp (VALMT):企業の財務・戦略的SWOT分析
    Valmet Corp (VALMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Security Devices International Inc.:企業の戦略・SWOT・財務情報
    Security Devices International Inc. - Strategy, SWOT and Corporate Finance Report Summary Security Devices International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆